The combined German and New York Stock Exchange must now find a suitable name for the newly merged trading floor. And as Stephen Beard explains, instead of using a brand consultant, the new exchange is going the social media route for suggestions.
French pharmaceutical company Sanofi-Aventis will pay more than $20.1 billion for U.S. biotech firm Genzyme. Sanofi will pay $74 per Genzyme share once the deal closes in the second quarter of 2011.
Wednesday brought an end to the long-awaited deal between French pharmaceutical company Sanofi-Aventis and the U.S. biotech firm Genzyme. Sanofi will buy Genzyme for at least $20.1 billion. But the number could go higher if Genzym's drugs-in-development succeed when they go to market, as Eve Troeh explains.
The parent company for the New York Stock Exchange has agreed to a merger with Germany's Deutsche Borse, pending regulatory approval. The deal will create the largest exchange for stocks and derivatives in the world. Heidi Moore explains.
The Wall Street Journal reports a U.S. government panel will recommend that President Obama veto a bid by China's Huawai Technologies Co. to buy the assets of Bay Area developer 3Leaf Systems. Rob Schmitz reports.
Kai Ryssdal talks to Teddy Weisberg, the president of Seaport Securities, about the potential merger of the New York Stock Exchange with Germany's Deutsche Borse AG.
Just one day after the London Stock Exchange announced a merger with the Toronto Stock Exchange, NYSE Euronext announced it is nearing a buy-out agreement with Deutsche Borse of Germany. David Gura has more.
Officials from the London Stock Exchange Group PLC and Toronto based TMX group Inc. announced the merger today. Bringing the two companies together will produce the second largest mining- and resource-exchange in the world. Christopher Werth explains.
